Pharmaceutical Technology

OCTOBER 12, 2023

Almirall will license EpimAb’s Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to develop up to three bispecific antibody targets.

Antibody 147

Antibody Development Licensing Licensing 147

Pharmaceutical Technology

OCTOBER 17, 2023

LegoChem Biosciences has entered an exclusive worldwide licensing agreement with Glycotope to develop an antibody-drug conjugate (ADC).

Antibody 130

Antibody Development Drugs Licensing 130

BioPharma Reporter

NOVEMBER 7, 2023

The German mRNA giant BioNTech has sealed a pact worth up to $1 billion with Biotheus to develop the Chinese biotech companyâs bispecific antibody cancer drug PM8002 in all territories except for Greater China.

Antibody 98

Antibody Licensing Licensing Drugs 98

Pharmaceutical Technology

APRIL 13, 2023

Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. ATV: Aβ uses Denali’s ATV technology to cross the blood-brain barrier (BBB) and increase brain exposure to antibodies.

Licensing 130

Licensing Licensing Antibody Clinical Trials 130

Bio Pharma Dive

MAY 25, 2023

Study abstracts released Thursday give investors and analysts a better look at cancer treatments recently licensed by Merck and BioNTech as well as fresh details on other closely watched ADC candidates.

Antibody 310

Antibody Licensing Licensing Drugs 310

Pharmaceutical Technology

JULY 21, 2022

AstraZeneca has signed a deal with the Federal Office of Public Health (FOPH) of Switzerland to deliver over 1,200 doses of antibody therapy, tixagevimab and cilgavimab combination (AZD7442), for Covid-19 prevention and treatment. In June 2020, these antibodies, discovered at Vanderbilt University Medical Center, were licensed to AstraZeneca.

Antibody 264

Antibody Compliance Clinical Trials Clinical Trials 264

Pharmaceutical Technology

OCTOBER 21, 2022

AbbVie has announced the acquisition of UK-based biotechnology firm DJS Antibodies for nearly $255m in cash at closing. DJS focuses on the discovery and development of antibody therapies that act on difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs).

Antibody 217

Antibody Protein Licensing Licensing 217

Pharmaceutical Technology

OCTOBER 13, 2023

MediLink will receive $70m upfront and will be eligible for up to $1bn in additional milestone-based payments from BioNTech.

Licensing 147

Licensing Licensing Antibody Drugs 147

Pharmaceutical Technology

JANUARY 9, 2023

Eisai and Biogen have received approval for their antibody Leqembi (lecanemab-irmb) , 100mg/mL injection for intravenous use, from the US Food and Drug Administration (FDA) under the Accelerated Approval Pathway to treat Alzheimer’s disease (AD). The regulatory approval is based on the data obtained from the Phase II trial.

FDA Approval 246

FDA Approval Antibody Clinical Trials Clinical Trials 246

Pharmaceutical Technology

OCTOBER 30, 2023

Helinus will receive €42m upfront and will be in line to receive up to €143m in regulatory and sales-based milestone payments.

Licensing 147

Licensing Licensing Antibody Marketing 147

Drug Discovery World

AUGUST 2, 2023

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. ” The post Renaissance Pharma licenses Hu14.18

Licensing 98

Licensing Licensing Antibody Trials 98

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement. The mAb is presently in the Phase II development stage.

Antibody 279

Antibody Genotype Licensing Licensing 279

BioPharma Reporter

APRIL 2, 2024

Ipsen is expanding its oncology pipeline by securing the global licensing rights to an antibody-drug conjugate (ADC) for solid tumors from Sutro Biopharma, its first drug in the category.

Licensing 52

Licensing Licensing Antibody Drugs 52

Pharmaceutical Technology

JULY 19, 2023

Twist Bioscience and CRUK innovation arm Cancer Research Horizons have signed an agreement for licensing a library of libraries.

Antibody 246

Antibody Research Licensing Licensing 246

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). Till date, the company has signed a total of 12 ADC licensing deals, worth more than $5bn.

Antibody 130

Antibody Development Drugs Licensing 130

BioSpace

OCTOBER 21, 2021

The license and collaboration agreement allows Janssen to use F-star’s proprietary technology in the research, development and commercialization of novel bispecific antibodies.

Licensing 78

Licensing Licensing Antibody Development 78

Pharmaceutical Technology

OCTOBER 19, 2022

Syncromune and Biocytogen Pharmaceuticals’ wholly owned subsidiary Eucure Biopharma have entered an exclusive global licence agreement for OX40 antibody YH002 and two other active ingredients. . Syncromune president and CEO Eamonn Hobbs said: “We are excited to enter into an exclusive licensing agreement with Eucure/Biocytogen.

Antibody 130

Antibody Licensing Licensing Containment 130

Drug Discovery World

JULY 21, 2023

Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. The post Partnership could enhance antibody discovery for cancer research appeared first on Drug Discovery World (DDW).

Antibody 98

Antibody Research Licensing Licensing 98

Pharmaceutical Technology

MARCH 28, 2023

On March 27, OncoVerity announced the acquisition of worldwide licensing rights of the anti-CD70 monoclonal antibody cusatuzumab from the biotech argenx. Alongside this, the company closed a $30 million Series A, which came from both argenx and the venture of UCHealth and the University License Equity Holdings.

Licensing 130

Licensing Licensing Development Antibody 130

BioSpace

DECEMBER 21, 2022

Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.

Licensing 93

Licensing Licensing Antibody Development 93

Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.

Antibody 130

Antibody Drugs Clinical Development Licensing 130

Bio Pharma Dive

APRIL 13, 2023

The program is part of Denali’s “transport vehicle” platform, which uses drugmaking technology to shepherd large therapeutic molecules like antibodies across the so-called blood-brain barrier.

Licensing 177

Licensing Licensing Antibody 177

Pharmaceutical Technology

JANUARY 6, 2023

Danish biotech company Adcendo has entered into a licence agreement with Duality Biologics on the next-generation antibody-drug conjugates (ADC) platform. The post Adcendo and Duality Biologics sign license deal for ADC platform appeared first on Pharmaceutical Technology.

Licensing 130

Licensing Licensing Antibody Development 130

Bio Pharma Dive

APRIL 3, 2023

The biotech is expanding its cancer medicine pipeline by licensing two experimental antibody drug conjugates from Shanghai-based Duality.

Licensing 287

Licensing Licensing Antibody Medicine 287

BioSpace

JULY 10, 2023

The biotech has acquired an exclusive global license for Shanghai-based DualityBio’s investigational antibody-drug conjugate for select solid tumors.

Licensing 67

Licensing Licensing Antibody Drugs 67

Pharmaceutical Technology

SEPTEMBER 16, 2022

The US Food and Drug Administration (FDA) has granted fast track designation to Jasper Therapeutics’ antibody, JSP191, for the treatment of severe combined immunodeficiency (SCID) patients who undergo allogeneic hematopoietic stem cell transplant. . The antibody was also analysed in a total of more than 110 healthy subjects and patients. .

Antibody 130

Antibody Clinical Trials Clinical Trials Licensing 130

BioPharma Reporter

OCTOBER 26, 2023

The biopharmaceutical industry witnessed a 400% growth in total deal value of antibody-drug conjugate (ADC) licensing agreements from 2017-2022 and reached a peak of $16.6 billion in 2022, reveals data and analytics company GlobalData.

Licensing 59

Licensing Licensing Antibody Drugs 59

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. To overcome this challenge, Synaffix has developed an innovative technology platform that can rapidly and efficiently convert any antibody into an ADC.

Antibody 98

Antibody Marketing Drugs Licensing 98

Drug Discovery World

NOVEMBER 2, 2023

This brought us to intersect with AION Labs, which had issued a call for applicants to launch a new company leveraging AI-based solutions for the computational de novo design of high-affinity antibodies for targeted therapies. RA: How laborious and expensive are current antibody discovery efforts? KS: In short, incredibly so.

Antibody 83

Antibody Protein Development Drugs 83

BioPharma Reporter

SEPTEMBER 2, 2021

Anti-CD25 antibodies have emerged as one of the most promising next-generation cancer therapeutics, says US plant-based manufacturer of therapeutics and vaccines, iBio, as it enters the field.

Antibody 111

Antibody Licensing Licensing Manufacturing 111

Bio Pharma Dive

OCTOBER 20, 2023

The deal is worth up to $22 billion in total, making it one of the largest pharmaceutical licensing agreements by value.

Antibody 148

Antibody Licensing Licensing Drugs 148

BioSpace

MARCH 14, 2024

Hansoh Pharma is licensing Biotheus’ anti-EGFR/cMet bispecific antibody to develop antibody-drug conjugates. The Chinese biotechs are broadening their collaboration.

Antibody 88

Antibody Licensing Licensing Development 88

BioTech 365

MAY 10, 2021

Hubrecht Institute Licenses Flow Eighteen38 Reagent Antibodies for Cancer Research Hubrecht Institute Licenses Flow Eighteen38 Reagent Antibodies for Cancer Research Antibodies generated by Flow Eighteen38 to be used as research tools by Hubrecht Institute.

Reagent 52

Reagent Licensing Licensing Antibody 52

BioPharma Reporter

JUNE 1, 2021

Corbus Pharmaceuticals announced the expansion of its portfolio into immuno-oncology through licensing deals with the University of California San Francisco and Panorama Research Inc for two new monoclonal antibodies (mAbs).

Licensing 52

Licensing Licensing Antibody Research 52

pharmaphorum

MAY 18, 2022

Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19. ” The post AstraZeneca buys into startup RQ Bio’s COVID antibodies appeared first on. .

Antibody 98

Antibody Licensing Licensing Medicine 98

BioPharma Reporter

JANUARY 6, 2023

Synaffix, a Netherlands based company providing clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), has signed off on two new licensing deals this week.

Licensing 52

Licensing Licensing Antibody Development 52

Bio Pharma Dive

JANUARY 7, 2022

Neurimmune, which will license to AstraZeneca an early-stage treatment for a rare form of cardiomyopathy, is probably best known for its invention of the antibody that became Biogen's Alzheimer's drug Aduhelm.

Drugs 281

Drugs Licensing Licensing Antibody 281